# Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders

> **NCT00684268** · PHASE2 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 70 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Silibinin
- **DRUG:** Silibinin

## Key facts

- **NCT ID:** NCT00684268
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2011-02
- **Final completion:** 2011-06
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2017-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00684268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00684268, "Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00684268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*